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Effects of EGFR Expression on Anti-tumor 
Efficacy of Vandetanib or Cediranib Combined 
with Radiotherapy (RT) in U87 Human
Glioblastoma (GBM) Xenografts
Introduction
Vandetanib is a receptor tyrosine kinase inhibitor (RTKI) with activity 
against vascular endothelial growth factor receptor-2 (VEGFR-2) 
and epidermal growth factor receptor (EGFR). Cediranib is a highly 
potent VEGF RTKI that inhibits all three VEGF receptors. In this 
study we investigated the effect of exogenous overexpression of 
EGFR on sensitivity of human GBM U87 xenografts to vandetanib 
or cediranib, alone or in combination with RT.
Methods
Animal and tumor model: Human U87 GBM cells, stably transfected 
with EGFR (U87 EGFR) or empty vector (U87 vector), were injected 
subcutaneously into the right hind limbs of athymic NCR NUM 
mice. Drug Administration: Vandetanib was dosed at 50mg/kg daily 
for two weeks starting on Day 0. Cediranib was dosed at 3 mg/kg 
daily for two weeks starting on Day 0. RT was administered as three 
daily fractions of 5 Gy on Days 0, 1 and 2. On the days that RT and 
vandetanib/cediranib were both given, drugs preceded RT by 1/2 
hour. Statistical Analysis: Mixed-effects linear regression was used 
to model tumor volume as a function of time and treatment Analysis 
of VEGF levels in U87 EGFR or U87 vector cells in culture: Cells were 
irradiated at doses between 0-10 Gy and incubated in the presence 
or absence of vandetanib (0-10 microM) or cediranib (0-10 nanoM) 
for 48 hrs. VEGF was assayed from culture supernatants using 
a commercially available human VEGF immunoassay kit (R&D 
Systems, Minneapolis, MN).
Results
Exogenous over-expression of EGFR altered tumor doubling time 
(T2x (days)) in U87 xenografts (2.70 for U87 EGFR vs. 4.41 for U87 
vector). In U87 EGFR xenografts, single agent RT, vandetanib or 
cediranib significantly increased tumor doubling time (T2x (days)) 
when compared to control (4.79 for RT; 6.32 for vandetanib and 5.00 
for AZD vs. 2.70 for control). In U87 vector xenografts, RT but not 
drugs significantly increased T2x (6.56 for RT vs. 4.41 for control).
In U87 EGFR xenografts, the combination of RT with vandetanib 
but not RT with cediranib was significantly better than RT alone 
(T2x = 10.37 for RT + vandetanib vs.4.79 for RT alone (p<0.001) 
implying radiosensitization. Neither drug radiosensitized U87-vector 
xenografts. In cell culture, radiation induced VEGF secretion from 
both U87-EGFR and U87-vector cells in a dose-dependent manner. 
Vandetanib (10 microM), but not cediranib suppressed radiation-
induced VEGF release in U87-EGFR cells and to a lesser extent, in 
U87-vector cells.
Conclusion
These data demonstrate that exogenous EGFR expression in U87 
human GBM xenografts appears to induce greater sensitivity to the 
combination of RT + vandetanib compared with RT + cediranib. 
This observation suggests that EGFR signaling may have a direct 
influence on U87 tumor radiosensitivity in vivo, or an indirect effect 
on the tumor vasculature or microenvironment, perhaps through 
upregulation of tumor derived growth factors such as VEGF. 
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